GUJTHEM430.00

Gujarat Themis Biosyn Limited

· Pharma & Health
₹ CrorePeersRPGLIFEGUFICBIOORCHPHARMAUNICHEMLABFDCIOLCPMOREPENLABINNOVACAPMcap ₹4,685 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Returns
Return on Common Equity19.6416.22
Return on Assets16.199.27
Return on Capital Employed22.6114.76
Return on Invested Capital17.7210.59
Margins
EBITDA Margin45.6545.55
Operating Margin42.0937.76
Incremental Operating Margin-5.72
Pretax Margin43.4637.44
Net Income Margin32.3428.15
FCF Margin-16.66-74.63
Additional
Effective Tax Rate25.5824.82
Dvd Payout Ratio3.7215.64
Sustainable Growth Rate18.9113.68
Incremental Operating Margin %-5.72
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.